Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin

被引:11
作者
Clarke, LE
Bayerl, MG
Bruggeman, RD
Mauger, D
Ioffreda, MD
Abou-Elella, A
Helm, KF
机构
[1] Penn State Univ, Coll Med, Dept Pathol, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[2] Penn State Univ, Coll Med, Dept Dermatol, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[3] Penn State Univ, Coll Med, Dept Hlth Evaluat Sci, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
关键词
lymphomatoid papulosis; anaplastic large cell lymphoma; CD30-positive lymphoproliferative disorders; FADD; caspase;
D O I
10.1097/01.pas.0000155154.46434.93
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Background: The CD30-positive lymphoproliferative disorders lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (C-ALCL), and systemic anaplastic large cell lymphoma (S-ALCL) are lesions that overlap clinically, histopathologically, and immunophenotypically. Their biologic behaviors, however, vary considerably. In particular, lesions of LyP regress spontaneously while those of S-ALCL persist and often progress. Apoptosis has been suggested as the mechanism by which the lesions of LyP regress, but the underlying signaling pathways remain unclear. In this study, we used newly developed activation state-specific antibodies to demonstrate apoptosis signaling through the death receptor-mediated pathway regulated by FADD and caspase 3. Methods: Dual immunohistochemistry for CD30 and activated forms of FADD and caspase 3 was performed on cutaneous biopsy specimens from 27 patients with CD30-positive lymphoproliferative disorders involving the skin. The patients included 18 with primary cutaneous CD30-positive LPDs (15 with LyP and 3 with C-ALCL) and 9 with S-ALCL. Results: The proportion of CD30-positive cells expressing activated FADD was significantly different between primary cutaneous CD30-positive lymphoproliferative disorders and S-ALCL (36.4% vs. 14.5%, P = 0.0083). Expression of cleaved caspase 3 was also significantly different between primary cutaneous lesions and S-ALCL (9.2% vs. 1.9%, P = 0.048). Conclusions: Although a larger number of cases should be studied to validate these results, these data provide evidence that differences in signaling through the death-receptor apoptosis pathway mediated by FADD may be responsible for the varying biologic behaviors of CD30-positive lymphoproliferative disorders involving the skin.
引用
收藏
页码:452 / 459
页数:8
相关论文
共 57 条
[1]
CD30+lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis [J].
Aoki, M ;
Niimi, Y ;
Takezaki, S ;
Azuma, A ;
Seike, M ;
Kawana, S .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 145 (01) :123-126
[2]
Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]
Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas [J].
Assaf, C ;
Hummel, M ;
Dippel, E ;
Schwartz, S ;
Geilen, CC ;
Harder, L ;
Siebert, R ;
Steinhoff, M ;
Klemke, CD ;
Thiel, E ;
Goerdt, S ;
Stein, H ;
Orfanos, CE .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) :488-491
[4]
Advances in cytochemical methods for detection of apoptosis [J].
Barrett, KL ;
Willingham, JM ;
Garvin, AJ ;
Willingham, MC .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2001, 49 (07) :821-832
[5]
Primary and secondary cutaneous CD30+ lymphoproliferative disorders:: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment [J].
Bekkenk, MW ;
Geelen, FAMJ ;
Vader, PCV ;
Heule, F ;
Geerts, ML ;
van Vloten, WA ;
Meijer, CJLM ;
Willemze, R .
BLOOD, 2000, 95 (12) :3653-3661
[6]
ALK-positive lymphoma:: A single disease with a broad spectrum of morphology [J].
Benharroch, D ;
Meguerian-Bedoyan, Z ;
Lamant, L ;
Amin, C ;
Brugières, L ;
Terrier-Lacombe, MJ ;
Haralambieva, E ;
Pulford, K ;
Pileri, S ;
Morris, SW ;
Mason, DY ;
Delsol, G .
BLOOD, 1998, 91 (06) :2076-2084
[7]
Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations [J].
Beylot-Barry, M ;
Groppi, A ;
Vergier, B ;
Pulford, K ;
Merlio, JP .
BLOOD, 1998, 91 (12) :4668-4676
[8]
Brugières L, 1998, BLOOD, V92, P3591
[9]
The same dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis [J].
Chott, A ;
Vonderheid, EC ;
Olbricht, S ;
Miao, NN ;
Balk, SP ;
Kadin, ME .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) :696-700
[10]
The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30(+) lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin [J].
DeCoteau, JF ;
Butmarc, JR ;
Kinney, MC ;
Kadin, ME .
BLOOD, 1996, 87 (08) :3437-3441